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Objective: A well-controlled study in patients with allergic asthma was warranted to assess
dose-dependency between fractional concentration of exhaled nitric oxide (FeNO) and sputum
eosinophils to a combination of an inhaled corticosteroid plus a long-acting b2-agonist. We
sought to characterize the dose-dependency of mometasone furoate/formoterol (MF/F) using
FeNO and sputum eosinophil percentage as surrogates of airway inflammation in subjects with
allergic asthma.
Methods: Following a 2-week, open-label run-in, 93 subjects (12 y) using only short-acting beta
agonist relievermedication as needed, were randomized to twice daily (BID) placebo; MF/F 100/
10 mg, 200/10 mg, or 400/10 mg (via pressurized metered-dose inhaler [MDI]); MF-MDI 200 mg; or
MF 200 mg via dry powder inhaler (DPI) during a 2-week, double-blind treatment period.8 298 4000.
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Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol 657Results: All active treatments demonstrated significant percentage reductions from baseline in
FeNO compared with placebo at all time points (P  0.034). At endpoint, mean MF/F treatment
group FeNO reductions ranged from 35.3% to 61.4%. Sputum eosinophil percentage reduc-
tions from baseline were significant compared with placebo for the MF/F 200/10 mg, MF/F
400/10 mg, and MF-DPI 200 mg groups at endpoint (P 0.023). Escalating MF/F doses significantly
reduced both FeNO (P  0.001) and sputum eosinophil (P  0.022) levels in a dose-dependent
manner at all time points. All treatments were well tolerated; no serious adverse events were
observed.
Conclusion: All 3 MF/F doses demonstrated pronounced, clinically meaningful, dose-dependent
reductions in FeNO, with reduced sputum eosinophil levels for MF/F 200/10 mg and MF/F 400/
10 mg. These findings suggest both inflammatory markers may be useful in assessing corticoste-
roid responsiveness in asthma patients, and perhaps identifying the same asthma subphenotype.
Clinical Trials.gov: NCT00635882.
ª 2013 Published by Elsevier Ltd.Introduction
Current asthma management guidelines indicate that the
goals of treatment include maintaining control of symp-
toms, normalization of lung function, and identification of
the minimum steroid dose needed to maintain control.1,2
While not listed explicitly, other goals may include pre-
vention or reduction of airway inflammation or hyper-
responsiveness.1,2 However, the effects of inhaled
corticosteroid (ICS)/long-acting b2-agonist (LABA) combi-
nation therapy on inflammation are not well characterized,
with conflicting evidence on pro- or anti-inflammatory ef-
fects. It is well known that ICSs have prominent anti-
inflammatory effects, whereas a recent meta-analysis
suggested that LABAs have little, if any, clinically mean-
ingful effect on airway inflammation.3 Further in-
vestigations of this point are warranted.
Pulmonary function tests identify abnormal airway phys-
iology and airflow obstruction, whereas fractional concen-
tration of exhaled nitric oxide (FeNO) and sputum eosinophil
counts are often used as markers of airway inflammation.
However, some data suggest that FeNO may also provide an
alternative to clinical measures in the evaluation of asthma
control and allow for more efficient titration of ICS treat-
ment.4 Sputum eosinophil counts have been shown convinc-
ingly to predict response to ICS treatment5e7 or the potential
for relapse when ICS treatment was withdrawn,8,9 and to be
an effective marker for ICS titration.10,11
Although a relationship between ICS therapy and re-
ductions in FeNO has been observed, responses may plateau
at lower ICS doses.12,13 However, these studies included
heterogenous populations of asthmatic patients among
whom the effect of ICSs would be difficult to assess. A well-
controlled study in patients with active eosinophilic airway
inflammation may provide a better opportunity to assess
the relationship between inflammation, FeNO levels,
sputum eosinophil percentage, and clinical response to ICS
treatment.
The objective of the current study (ClinicalTrials.gov
identifier: NCT00635882) was to characterize the dose-
responsiveness of mometasone furoate/formoterol (MF/F;
Dulera; Schering Corporation, a subsidiary of Merck & Co.,
Inc., Whitehouse Station, NJ USA) using FeNO and sputumeosinophil percentage as surrogate variables for airway
inflammation.
Methods
Study population
Eligible asthma patients were 12 years of age with a
diagnosis of allergic asthma for 12 months; allergic
asthma subjects were identified with a positive allergen
skin test or specific serum IgE measurements.
Inclusion criteria
Subjects were required to have a FEV1 >65% predicted at
screening and baseline, and were required to demonstrate
1 of the following at screening or any time between
screening and baseline: 1) an increase in absolute FEV1
12% and 200 mL within 20 min after administration of 4
inhalations of albuterol (salbutamol; total dose,
360400 mg) or a nebulized short-acting b2-agonist (SABA;
2.5 mg); 2) a PEF variability of >20% of the mean highest
and lowest morning prebronchodilator PEF value over 1
week; or 3) a diurnal PEF variation of >20% of the differ-
ence between prebronchodilator morning PEF and post-
bronchodilator PEF from the evening before the open-label
run-in period. Additional inclusion criteria were both FeNO
>30 ppb at a flow rate of 50 mL/s and sputum eosinophil
count >3% of total non-squamous cell count prior to
baseline.
Exclusion criteria
Key exclusion criteria were use of systemic corticosteroids,
oral or high potency topical corticosteroids 3 months
before screening; upper or lower respiratory tract infection
4 weeks before screening; a decrease in absolute FEV1 of
>20% between screening and baseline; use of >8 in-
halations/day of a SABA-MDI or 2 nebulized treatments of
a SABA 2.5 mg on 2 consecutive days between screening and
baseline; a decrease in AM or PM PEF below the run-in
period stability limit on 2 consecutive days prior to base-
line; clinical asthma deterioration requiring emergency
treatment, hospitalization due to asthma, or treatment
with excluded asthma medication (oral or other systemic
658 H. Nolte et al.corticosteroids) between screening and baseline; and
inability to perform sputum induction with 2 attempts.
Study design
This randomized, 2-week, double-blind, double-dummy,
placebo-controlled study was conducted in 26 study cen-
ters in North America and Europe in accordance with Good
Clinical Practice. Before study initiation at each study
site, the protocol was reviewed and approved by an
institutional review board or independent ethics commit-
tee. Written informed consent was obtained from each
subject or his/her parent or guardian before any study-
related activity.
Eligible subjects underwent a 2-week, open-label run-in
period, with only prn SABA rescue medication to minimize
any anti-inflammatory effects of treatment prior to
randomization and to maximize FeNO and sputum eosinophil
levels at baseline. At baseline, subjects were randomized to
2-week (15-day) double-blind twice daily treatment with
placebo-MDI; placebo dry powder inhaler (DPI); MF/F 100/
10 mg, 200/10 mg, 400/10 mg (all via MDI); MF-MDI 200 mg; or
MF 200 mg via a DPI. Subjects were instructed to take two
inhalations from the MDI (active or placebo) each morning
and evening, approximately 12 h apart, and one inhalation
from the DPI (active or placebo) each morning and evening,
approximately 12 h apart. Randomization was performed
according to a computerized random number schedule.
Clinic visits were scheduled at screening, prebaseline, and
on days 1 (baseline), 7, 14, and 15.
Assessments
FeNO
The percentage change in FeNO from baseline to day 14 was
the primary study endpoint; the percentage change from
baseline to day 7 was a secondary endpoint. The percent-
age change from baseline to endpoint (last observation
carried forward [LOCF]) was also evaluated. FeNO was
measured online, using the Nitric Oxide Analyzer (NIOX;
Aerocrine AB; Solna, Sweden), a monitoring system that
utilizes biofeedback to maintain a constant expiratory flow
rate at the standard recommended rate of 0.05 L/s at each
measurement. Measurements were performed according to
ATS guidelines.14
Sputum eosinophils
The percentage change in sputum eosinophil count from
baseline to day 14 was a secondary study endpoint; changes
from baseline to day 7 and endpoint and median sputum
eosinophil count at endpoint were also evaluated. Sputum
induction was conducted according to ERS recommenda-
tions: after inhalation of 1 mg terbutaline, sputum was
induced by inhalation of hypertonic saline in increasing
concentrations (3%, 4% and 5%) for 3 time periods each of
7 min (total duration, 21 min).15 Sputum plugs were
selected and processed, cytospins were prepared using
standard methods, and a differential cell count was per-
formed. All slides were read and interpreted as previously
described16 at a central laboratory supervised by Dr Har-
greave and Dr Nair.Lung function, symptoms, and bronchial provocation
Changes in PEF and asthma symptoms from baseline to day
2e15 (average; recorded in AM upon awakening) or day 1e15
(average; recordedapproximately12hafter theAMrecording
[PM]) were additional secondary study endpoints. PEF was
recorded using an electronic diary (e-diary) that included a
mouthpiece to capture peak flow. The flow-volume sensor of
this system complied with current ATS/ERS standards.17
Before administration of study drug or SABAs, subjects
completed 3 PEF measurements (AM and PM), the best of
which was recorded in the e-diary. Asthma symptoms were
also recorded twice daily, before the use of studymedication
or SABAs (AM and PM). Subjects evaluated wheezing, diffi-
culty breathing, and cough as experienced during the time
since the last evaluation, and recorded responses on a 4-point
scale in the e-diary. Response options ranged from 0 (none;
“sign/symptom is not present”) to 3 (severe; “sign/symptom
very uncomfortable and interfered with most or all of my
normal daily activities/sleep”). Total asthma symptom scores
were derived by adding the wheezing, difficulty breathing,
and coughing evaluation scores.
The change from baseline to day 15 in the provocative
dose of mannitol required to produce a 15% reduction in the
FEV1 (PD15) was another secondary study endpoint. Bron-
chial provocation with mannitol powder (Aridol; Phar-
maxis; Frenchs Forest, Australia) contained in capsules and
inhaled from an Osmohaler dry powder inhaler (Plastiape,
Osnago, Italy) up to a cumulative dose of 635 mg was per-
formed as previously described.18,19 Based on the findings
in healthy non-asthmatics, a 15% decrease in FEV1 to
635 mg or less is regarded as a positive response and in-
dicates airway hyperresponsiveness (AHR). The cumulative
dose of methacholine or mannitol required to provoke a
PD15 was calculated by interpolation of the log-linear
doseeresponse curve.
Safety
Safety was assessed by monitoring adverse events and vital
signs.
Statistical analyzes
The predefined statistical analysis planned for all study as-
sessments was a one-way analysis of variance (ANOVA)
model with treatment effect. However, because of varia-
tions between treatment groups in baseline values, FeNO
levels, sputum eosinophil counts, and mannitol challenge
tests were analyzed using an analysis of covariance
(ANCOVA) with treatment effect and baseline as covariates
as described below. The power calculation prior to the study
showed that a population of 12 subjects per treatment group
at day 14 were required to analyze the primary variable in
this study (change from baseline in FeNO) with 90% power
and alpha of 0.05 to detect a treatment difference (MF/F
400/10 mg vs placebo) of 28% assuming a pooled standard
deviation of 20%. Secondary endpoints were analyzed using
ANCOVA, but were not powered to detect treatment dif-
ferences. All efficacy and safety variables were analyzed for
all randomized subjects (intent-to-treat principle).
The mean percentage changes from baseline in FeNO and
sputum eosinophil counts (days 7 and 14, and endpoint
[LOCF]) were least squares (LS) means based on an ANCOVA
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Pairwise comparisons of median sputum eosinophil counts at
endpoint (LOCF) were made using the Wilcoxon rank-sum
test. Mean changes from baseline in AM and PM PEF and
symptom scores (average of day 2e15 [AM] and 115 [PM])
were LS means based on a one-way ANOVA model with
treatment effect. Mean changes from baseline in cumulative
mannitol dose from baseline to day 15 were LS means based
on an ANCOVA model with treatment effect and baseline as
covariates. All trend (dose response) tests for all analyzes
included a linear contrast of placebo and the 3 dose levels of
MF/F based on the ANCOVA or ANOVA model estimate.
FeNO and sputum eosinophil data were also examined
post hoc per recent ATS/ERS guidance and publications,
which describe 2-fold reductions from baseline as clini-
cally meaningful.20 As such, reductions from baseline in
log10 fold change were analyzed by ANCOVA with treat-
ment and baseline log10 FeNO or sputum eosinophil levels
as covariates. Mannitol challenge data were also explored
by deriving and analyzing the response dose ratio (RDR),
which is the final recorded percentage decrease in FEV1
divided by the cumulative dose of mannitol required to
induce that decrease. ANCOVA was performed on the log-
transformed data, with the log-transformed RDR at base-
line as a covariate. The fold reductions for each were
obtained by back-transforming the ANCOVA model esti-
mates. Mean fold reductions are presented with 95% con-
fidence intervals (CIs).
Results
Disposition, demographics, and baseline
characteristics
A total of 93 subjects were randomized to treatment
(Fig. 1). All subjects completed the treatment protocol,
except 1 in the MF/F 100/10 mg BID group who was dis-
continued due to noncompliance.
Demographic characteristics are presented in Table 1. A
total of 55% of subjects had previous ICS or ICS/LABA therapy
and were switched to as-needed SABA therapy at screening.
There were no noticeable differences between FEV1 mea-
surements taken at screening and baseline, suggesting that
lung function was unchanged during the ICS washout.
Furthermore, baseline FEV1 measurements were compara-
ble between treatment groups. Baseline FeNO values ranged
from 54.8 to 102.6 ppb across treatment groups (Table 1).
FeNO
At all measured time points, all active treatment groups
demonstrated FeNO percentage changes from baseline that
were statistically significant compared with placebo (Fig. 2)
and escalating doses of MF/F reduced FeNO in a dose-
dependent manner (test for dose response, P  0.001).
Rapid, dose-related reductions of FeNO occurred in the MF/
F 100/10 mg, MF/F 200/10 mg, and MF/F 400/10 mg groups,
with reductions of 37.9%, 39.7%, and 45.6%, respectively, at
Day 7. All active treatment groups demonstrated higher
FeNO fold reductions from baseline versus placebo at all
measured time points (Supplementary Materials).Sputum eosinophils
The MF/F 400/10 mg and MF-DPI 200 mg treatment groups
demonstrated percentage changes from baseline in sputum
eosinophil counts thatwere statistically significant compared
with placebo at all measured time points (Fig. 3). Positive
changes from baseline in sputum eosinophil percentage
count observed in theMF/F 100/10 mg treatment group at day
14 and endpoint (Fig. 3) were attributed to 2 outliers (per-
centage changes from baseline333% at day 14 and endpoint
in both outliers). Although it appears that the level of eo-
sinophils increased in the MF/F 100/10 group, mean per-
centage reductions from baseline in mean sputum eosinophil
counts for the MF/F 100/10, 200/10, and 400/10 groups were
5.9, 6.9, and 7.3%, respectively. MF/F reduced sputum
eosinophil counts in a dose-dependent manner at all
measured time points (test for dose response, P  0.022).
Median sputum eosinophil counts at endpoint were: placebo,
10%; MF/F 100/10 mg, 2.2% (PZ 0.023 vs placebo); MF/F 200/
10 mg, 1.7%; MF/F 400/10 mg, 0.5% (P  0.033 vs placebo
and MF/F 100/10 mg); MF-MDI 200 mg, 2.3%; and MF-DPI
200 mg, 1.0% (PZ 0.001 vs placebo).
With the exception of the MF/F 100/10 mg group, all
active treatment groups demonstrated higher sputum
eosinophil fold reductions from baseline compared with
placebo at day 7, day 14, and/or endpoint (Supplementary
Materials). Sputum eosinophil reductions occurred rapidly
in the MF/F 200/10 mg and MF/F 400/10 mg groups, with
reductions of 48.5% and 73.4%, respectively, at Day 7.
AM and PM PEF
At baseline, mean AM PEF ranged from 413 L to 473 L across
treatment groups. Mean percentage changes from baseline
in AM PEF observed for all active treatment groups were
significantly superior compared with placebo (Fig. 4). Be-
tween active treatment groups, MF/F 400/10 mg was
significantly superior to MF-DPI 200 mg and MF-MDI 200 mg
(Fig. 4).
Baseline and mean percentage changes from baseline in
PM PEF values were similar to those observed for AM PEF
(data not shown). However, only the MF/F 100/10 mg and
MF/F 400/10 mg treatment groups experienced PM PEF
changes that were significantly superior to placebo
(P  0.005). Between active treatment groups, MF/F 400/
10 mg was superior to MF/F 200/10 mg, MF-MDI 200 mg, and
MF-DPI 200 mg (P  0.046).
Both AM and PM PEF changes increased in a
doseeresponse manner across escalating doses of MF/F
(tests for dose response, P  0.001).
AM and PM symptoms
Mean AM total asthma symptom scores at baseline were
mild or moderate (range, 1.2e2.2) across all treatment
groups; mean changes from baseline were: placebo, 0.2;
MF/F 100/10 mg, 0.7; MF/F 200/10 mg, 0.7; MF/F 400/
10 mg, 1.5 (P  0.018 vs placebo and MF-MDI 200 mg); MF-
MDI 200 mg, 0.5; and MF-DPI 200 mg, 1.2.
Mean PM total asthma symptom scores at baseline were
mild or moderate (range, 1.1e2.1) across all treatment
groups; mean changes from baseline were: placebo, 0.3;
Figure 1 Subject disposition. BID Z twice daily; DPI Z dry powder inhaler; MDI Z metered-dose inhaler; MF Z mometasone
furoate; MF/F Z mometasone furoate/formoterol.
Table 1 Demographics and baseline characteristics.
Variable MF/F MDI BID MF BID Placebo BID
(n Z 13)100/10 mg
(n Z 20)
200/10 mg
(n Z 17)
400/10 mg
(n Z 12)
MDI 200 mg
(n Z 16)
DPI 200 mg
(n Z 15)
Demographic
Sex, female, n (%) 13 (65) 10 (59) 4 (33) 6 (38) 6 (40) 8 (62)
Race, white, n (%) 20 (100) 12 (71) 11 (92) 16 (100) 14 (93) 12 (92)
Age, y, mean (SD) 34.4 (10.5) 43.0 (14.9) 39.8 (15.2) 32.6 (13.2) 32.0 (10.4) 42.2 (15.1)
BMI, kg/m2, mean (SD) 25.3 (5.6) 25.0 (4.0) 25.6 (3.6) 24.9 (5.0) 25.1 (4.3) 25.5 (5.3)
Asthma-related
Asthma duration, y, mean (SD) 19.7 (13.1) 27.4 (16.4) 20.1 (12.0) 14.2 (13.2) 13.8 (7.8) 23.5 (12.6)
Prior ICS with or without LABA
use, n (%)
8 (40) 13 (76) 10 (83) 5 (31) 7 (47) 8 (62)
FEV1, mean (SD)
Screening
L 3.1 (0.8) 2.7 (0.9) 3.3 (0.7) 3.4 (0.9) 3.3 (0.7) 3.1 (1.0)
Percentage predicted 85.2 (11.2) 77.8 (14.3) 85.0 (6.9) 83.2 (13.7) 83.3 (10.6) 89.6 (14.0)
Percentage reversibility 18.3 (8.1) 22.6 (14.4) 21.2 (11.5) 18.0 (11.4) 17.0 (6.2) 19.9 (7.3)
Baselinea
L 3.2 (0.9) 2.8 (0.9) 3.3 (0.7) 3.5 (0.8) 3.5 (0.8) 3.1 (1.0)
Percentage predicted 86.7 (12.5) 78.7 (14.5) 85.8 (4.3) 84.8 (11.8) 86.5 (10.4) 90.5 (14.4)
FeNO,b mean, ppb 54.8 70.0 77.1 66.2 102.6 79.6
Sputum EOS, mean, % 12.5 12.7 14.3 15.6 18.6 13.9
Allergy-related
Seasonal AR, n (%) 15 (75) 13 (76) 8 (67) 13 (81) 14 (93) 10 (77)
Perennial AR, n (%) 17 (85) 16 (94) 11 (92) 13 (81) 13 (87) 11 (85)
AR Z allergic rhinitis; BID Z twice daily; BMI Z body mass index; DPI Z dry powder inhaler; EOS Z eosinophil; FeNO Z fractional
concentration of exhaled nitric oxide; ICS Z inhaled corticosteroid; LABA Z long-acting b2-agonist; MDI Z metered-dose inhaler;
MF Z mometasone furoate; MF/F Z mometasone furoate/formoterol.
a Percentage reversibility not available at baseline.
b Sample sizes differ from those in column headers for the following groups: MF/F MDI 100/10 mg, nZ 19; MF/F MDI 200/10 mg, nZ 16;
MF-DPI 200 mg, n Z 14; MF-MDI 200 mg, n Z 15.
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Figure 2 Percentage change from baseline in FeNO at day 7 and day 14 and endpoint. BID Z twice daily; DPI Z dry powder
inhaler; FeNO Z fractional concentration of exhaled nitric oxide; MDI Z metered-dose inhaler; MF Z mometasone furoate; MF/
F Z mometasone furoate/formoterol. Error bars represent standard error of the mean.
Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol 661MF/F 100/10 mg, 0.4; MF/F 200/10 mg, 0.6; MF/F 400/
10 mg, 1.4 (P  0.037 vs placebo and MF/F 100/10 mg); MF-
MDI 200 mg, 0.7; and MF-DPI 200 mg, 1.1.
Both AM and PM changes from baseline in total symptom
score increased in a doseeresponse manner across esca-
lating doses of MF/F (tests for dose response, P  0.033).
Mannitol challenge
All active treatments afforded more protection against
bronchial hyperresponsiveness compared with placebo, asFigure 3 Percentage change from baseline in sputum eosinoph
DPI Z dry powder inhaler; MDI Z metered-dose inhaler; MF Z m
Error bars represent standard error of the mean.evidenced by mean change (mean percentage change) in
PD15: placebo (n Z 9), 63.7 (20.0%); MF/F 100/10 mg
(n Z 12), 176.6 (735.4%); MF/F 200/10 mg (n Z 9), 153.8
(587.6%); MF/F 400/10 mg (n Z 6), 162.9 (311.4%); MF-MDI
200 mg (n Z 9), 146.2 (186.7%); and MF-DPI 200 mg
(n Z 8), 159.4 (159.6%). Log-transformed results for PD15
support the relatively greater protection with active
treatment compared with placebo (Table 2). Due to the
substantial reduction in the number of observations in this
analysis (31%e47% of subjects in each group did not achieve
a positive mannitol challenge test or had missing data andil count at day 7, day 14, and endpoint. BID Z twice daily;
ometasone furoate; MF/F Z mometasone furoate/formoterol.
Figure 4 Percentage change from baseline in AM peak
expiratory flow at day 2e15 (Average). AM Z morning;
BIDZ twice daily; DPIZ dry powder inhaler; MDIZ metered-
dose inhaler; MFZmometasone furoate; MF/FZmometasone
furoate/formoterol; PEF Z peak expiratory flow. Error bars
represent standard error of the mean.
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(trend test, P Z 0.150), and only the MF/F 100/10 mg
treatment group achieved a statistically significant differ-
ence versus placebo (P Z 0.048). Similar results were
observed in the RDR of the mannitol challenge test
exploratory analysis (Table 3); MF/F 100/10 mg and MF/F
200/10 mg fold reductions from baseline to day 15 were
statistically superior to placebo (Supplementary Materials).
Safety
The percentage of subjects reporting treatment-related
adverse events was low (5.4% overall). The only severe
adverse event (oropharyngeal pain) occurred in the MF-MDI
200 mg treatment group, and was considered to be unlikely
related to treatment. There were no serious adverse events
during the study.
Discussion
This study demonstrated the dose-dependent positive ef-
fects of MF/F on FeNO and the percentage of eosinophils in
sputum in a group of patients with allergic asthma who usedTable 2 Change from baseline in log(PD15) for mannitol challe
Visit MF/F MDI BID
n 100/10 mg n 200/10 mg n 400/10
Baseline 12 3.9 9 3.3 6 4.0
Change from
baseline (%)
Day 15 and
endpointa
12 0.7 (31.5) 9 1.1* (62.2) 6 1.1* (34
BIDZ twice daily; DPIZ dry powder inhaler; MDIZ metered-dose in
formoterol; PD15 Z provocative dose of mannitol required to produc
*P < 0.05 vs placebo.
a Day 15 and endpoint (last observation carried forward) data wereonly SABA rescue medication for 2 weeks before randomi-
zation. The effects of MF/F on inflammation were observed
after just 7 days of treatment with a trend of further
improvement after 14 days. The combination did not have
any additional anti-inflammatory effects compared with
inhaled MF monotherapy after 14 days of treatment.
Demonstration of a doseeresponse relationship with
clinically relevant outcomes with ICSs has been problematic
for both clinical researchers and regulatory authorities.21
Traditional outcomes such as FEV1 and PEF are sensitive
only when the level of lung function is low or highly variable
to begin with and asthma is uncontrolled. Therefore, it is
difficult to recruit adequate numbers of such subjects to
participate in clinical trials. In contrast, it is easier to
demonstrate a doseeresponse to biomarkers, and the most
commonly studied are FeNO,22 sputum eosinophils,6 and
measures of airway responsiveness in response to direct
(eg, methacholine) or indirect (eg, adenosine mono-
phosphate, mannitol, exercise, or allergen) airway provo-
cation challenges. While FeNO, sputum eosinophils, and
indirect challenge responses can be demonstrated rela-
tively quickly, the changes in methacholine responses are
demonstrated over a prolonged period of time.6 Mometa-
sone, in particular, has been demonstrated to show a dose-
dependent attenuation of allergen-induced late asthma
response and sputum eosinophils.23 Consistent with these
findings, we observed dose-dependent MF/F effects on
FeNO and sputum eosinophils as early as day 7, particularly
because we had ensured that there was a signal by
selecting patients who had raised levels of both biomarkers
at baseline. Because the presence of eosinophils in sputum
or raised FeNO are markers of corticosteroid responsive-
ness, we were able to demonstrate a doseeresponse with a
relatively small number of subjects. The number of sub-
jects was, however, within the sample size calculation prior
to the study start.
The anti-inflammatory effects were due to the MF
component of the combination, as we did not observe
consistent differences between the combination doses and
those of MF alone administered either by DPI or by MDI. This
result parallels findings of a recent meta-analysis that did
not demonstrate any clinically relevant effects either on
sputum or bronchial mucosal eosinophils or FeNO in adults
or in children receiving a LABA alone.3 They also found
synergies with the combination. Collectively, these data
suggest that the anti-inflammatory synergy reported in ex-nge.
MF BID n Placebo BID
mg n DPI 200 mg n MDI 200 mg
8 4.6 9 4.3 9 4.7
.0) 8 1.1* (17.9) 9 0.7 (18.3) 9 0.2 (9.0%)
haler; MFZ mometasone furoate; MF/FZ mometasone furoate/
e a 15% reduction in FEV1.
identical for this assessment.
Table 3 Log transformed analysis of covariance for mannitol RDR.
Visit MF/F MDI BID MF BID n Placebo BID
n 100/10 mg n 200/10 mg n 400/10 mg n DPI 200 mg n MDI 200 mg
Baseline 19 0.111 14 0.343 11 0.114 15 0.096 16 0.042 12 0.097
Day 15 19 0.030* 14 0.023* 11 0.031 15 0.036 16 0.046 12 0.095
BIDZ twice daily; DPIZ dry powder inhaler; MDIZ metered-dose inhaler; MFZ mometasone furoate; MF/FZ mometasone furoate/
formoterol; RDR Z response dose ratio.
*P  0.036 vs placebo.
Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol 663vivo systems such as cultured smooth muscle cells, fibro-
blasts, or epithelial cells24 do not translate into clinically
relevant in-vivo effects on the measures we have assessed.
On the other hand, LABAs did not worsen inflammatory
parameters, which provides reassurance that LABA therapy
should not influence FeNO or sputum eosinophil evalua-
tions. To the best of our knowledge, this is the first attempt
to study the dose-dependent effects of a combination of an
ICS and a LABA using measurements of airway inflammation
and a direct measure of airway responsiveness.
The sputum eosinophil data suggest that MF-DPI may
have a superior anti-inflammatory effect to that of MF-MDI.
As reviewed by Geller,25 while MDIs are clinically equivalent
to DPIs, MDIs are associated with higher patient error rates,
and it is possible that aspects of the devices themselves
may have contributed to the observed sputum eosinophil
differences. However, none of the other endpoints sug-
gested significant differences between the MF-DPI and -MDI
groups, and additional analyzes in a larger population of
subjects would be necessary to examine this result further.
Surprisingly, positive changes from baseline in sputum
eosinophil counts were observed in the MF/F 100/10 mg BID
group at day 14 and endpoint. However, this finding was
attributed to 2 outliers who did not have elevated FeNO
levels (data not shown), which suggests that MF/F 100/
10 mg BID did not exacerbate airway inflammation.
It is of interest to note that the pronounced lung
inflammation was clearly not reflected by symptom scores
or FEV1 (data not shown), which overall indicated only mild
asthma at baseline. All 3 MF/F doses demonstrated a
modest and significant improvement versus placebo in PEF,
which patients measured in the morning upon rising (in
contrast to FEV1), but little effects on asthma symptoms
were noted. However, both MF/F 200/10 mg and MF/F 400/
10 mg normalized FeNO and sputum eosinophil levels.
Furthermore, all three doses of MF/F demonstrated on
average a minimally important decrease of FeNO of more
than 20% after treatment initiation suggesting that the
treatment was successful in reducing lung inflammation.26
Therefore, underlying inflammation, dosing, and ICS
treatment effects may not be adequately assessed by
measures of airway flow and symptoms alone.
Study limitations included the 2-week treatment period
and a suboptimal overall sample size. A larger population of
patients followed for a longer period of time (eg, 34
weeks) may have allowed for observation of more robust
treatment effects and provided the opportunity to evaluate
correlates between inflammatory marker changes and
quality of life improvements. Another limitation was thevariation in baseline FeNO measurements. Ideally, the
baseline characteristics and distributions would have been
more consistent between treatment groups. However, the
ANCOVA model used to analyze these data accounted for
these variations and allowed for the generation of clinically
meaningful findings.
In summary, this study demonstrated the dose-
dependent effects of MF/F as early as day 7 in subjects
with high baseline FeNO levels and sputum eosinophil
counts. MF/F demonstrated reductions in both inflamma-
tory markers, suggesting that FeNO levels and sputum
eosinophil counts may both be useful in titrating the ICS
dose and identifying the same asthma subphenotype.
Collectively, the data suggest that MF/F is an effective
therapy for persistent asthma by attenuating airway
inflammation and airway responsiveness.
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